Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJC7NF)

• Drug Name: FERULIC ACID Drug Info
• Synonyms: ferulic acid; trans-Ferulic Acid; 1135-24-6; 4-Hydroxy-3-methoxycinnamic acid; 537-98-4; trans-4-Hydroxy-3-methoxycinnamic acid; 3-(4-Hydroxy-3-methoxyphenyl)acrylic acid; (E)-Ferulic acid; ferulate; Coniferic acid; Ferulic acid, trans-; (2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid; 3-(4-Hydroxy-3-methoxyphenyl)-2-propenoic acid; Cinnamic acid, 4-hydroxy-3-methoxy-; 3-methoxy-4-hydroxycinnamic acid; (E)-3-(4-Hydroxy-3-methoxyphenyl)-2-propenoic acid; UNII-AVM951ZWST; Cinnamic acid, 4-hydroxy-3-methoxy-, (E)-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 445858
  ChEBI ID: CHEMBL32749
  CAS Number: CAS 537-98-4
  TTD Drug ID: DMJC7NF
  INTEDE Drug ID: DR2602

Molecule-Related Drug Atlas

Drug(s) Targeting Carbonic anhydrase VI (CA-VI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[9]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[10]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[11]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[1]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[12]
SAR566658	DM6Q295	Solid tumour/cancer	2A00-2F9Z	Phase 2	[13]
SPERMINE	DMD4BFY	N. A.	N. A.	Terminated	[14]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[1]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[15]
CATECHIN	DMY38SB	Discovery agent	N.A.	Investigative	[11]

Drug(s) Targeting Carbonic anhydrase I (CA-I)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[9]
Ethoxzolamide	DMVO4ED	Glaucoma/ocular hypertension	9C61	Approved	[16]
Dichlorphenamide	DMH7IDQ	Chronic glaucoma	9C61.0Z	Approved	[16]
Methazolamide	DM7J2TA	Glaucoma/ocular hypertension	9C61	Approved	[17]
Acetazolamide	DM1AF5U	Absence epilepsy		Approved	[16]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[11]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[1]
CG-100649	DMIKMA9	Arthritis	FA20	Phase 3	[18]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[11]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[12]

Drug(s) Targeting Carbonic anhydrase XII (CA-XII)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[9]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[19]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[11]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[1]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[11]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[12]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[1]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[15]
CATECHIN	DMY38SB	Discovery agent	N.A.	Investigative	[11]
GALLICACID	DM6Y3A0	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Carbonic anhydrase II (CA-II)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[9]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[19]
Dorzolamide	DMA17D0	Ocular hypertension	9C61.01	Approved	[20]
Chlorothiazide	DMLHESP	Chronic heart failure	BD1Z	Approved	[21]
Ethoxzolamide	DMVO4ED	Glaucoma/ocular hypertension	9C61	Approved	[22]
Dichlorphenamide	DMH7IDQ	Chronic glaucoma	9C61.0Z	Approved	[22]
Cyclothiazide	DMJ4AWC	Congestive heart failure	BD10	Approved	[23]
Ethinamate	DMK57GB	Insomnia	7A00-7A0Z	Approved	[24]
Benzthiazide	DMQWZ0H	High blood pressure	BA00	Approved	[25]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[11]

Drug(s) Targeting Carbonic anhydrase XIV (CA-XIV)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[26]
TRIENTINE	DMD2WPG	Inborn error of metabolism	5C50-5C59	Approved	[14]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[11]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[1]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[11]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[12]
SPERMINE	DMD4BFY	N. A.	N. A.	Terminated	[14]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[1]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[15]
CATECHIN	DMY38SB	Discovery agent	N.A.	Investigative	[11]

Drug(s) Targeting Carbonic anhydrase (CA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[27]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[10]
Quinethazone	DMWCOSR	Hypertension	BA00-BA04	Approved	[28]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[11]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[1]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[11]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[12]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[29]
PMID30074415-Compound-21	DM3NPOU	N. A.	N. A.	Patented	[30]
Imatinib and nilotinib derivative 2	DM34NZ8	Cas mediated disorder	N.A.	Patented	[30]

Drug(s) Targeting Carbonic anhydrase IV (CA-IV)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[9]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[31]
Brinzolamide	DMBAPFG	Ocular hypertension	9C61.01	Approved	[16]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[11]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[1]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[11]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[12]
Sodium pyruvate	DMST6A3	Asthma	CA23	Phase 1/2	[32]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[29]
SPERMINE	DMD4BFY	N. A.	N. A.	Terminated	[14]

Drug(s) Targeting Carbonic anhydrase IX (CA-IX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[11]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[1]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[11]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[12]
INDISULAM	DM9SX6Y	Lymphoma	2A80-2A86	Phase 2	[33]
Girentuximab I-124	DMG3O2Z	Renal cell carcinoma	2C90	Phase 2	[34]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[35]
BAY 79-4620	DM14XQN	Solid tumour/cancer	2A00-2F9Z	Phase 1	[36]
90Y-cG250	DMJR6TC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[37]
PMID30074415-Compound-GS3	DM2G8DN	N. A.	N. A.	Patented	[30]

Drug(s) Targeting Monoamine oxidase type B (MAO-B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selegiline Hydrochloride	DM3VR1L	Parkinson disease	8A00.0	Approved	[38]
Phenelzine	DMHIDUE	Depression	6A70-6A7Z	Approved	[39]
Tranylcypromine	DMGB5RE	Major depressive disorder	6A70.3	Approved	[40]
Selegiline	DM6034S	Major depressive disorder	6A70.3	Approved	[41]
Safinamide mesylate	DM0J2ZT	Parkinson disease	8A00.0	Approved	[42]
Rasagiline	DM3WKQ4	Parkinson disease	8A00.0	Approved	[43]
Sulphadoxine	DMZI2UF	Malaria	1F40-1F45	Approved	[44]
Pargyline	DMM0HR1	Hypertension	BA00-BA04	Approved	[45]
Indeloxazine	DMWO3N6	Dementia	6D80-6D86	Approved	[46]
Budipine	DMODHQI	Migraine	8A80	Approved	[47]

Drug(s) Affected By Stearoyl-CoA desaturase (SCD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[48]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[49]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[49]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[50]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[51]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[52]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[49]
Fructose	DM43AN2	Vomiting	MD90	Approved	[53]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[54]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[49]

Drug(s) Affected By Retinoblastoma-associated protein (RB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[55]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[56]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[57]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[58]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[59]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[60]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[61]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[62]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[63]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[64]

Drug(s) Affected By Mitogen-activated protein kinase 3 (MAPK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[65]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[66]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[67]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[68]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[69]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[70]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[71]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[72]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[73]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[74]

Drug(s) Affected By Mitogen-activated protein kinase 1 (MAPK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[75]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[66]
Carvedilol	DMHTEAO	Chronic heart failure	BD1Z	Approved	[76]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[77]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[78]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[65]
Urokinase	DM0GOUD	Myocardial infarction	BA41-BA43	Approved	[79]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[80]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[68]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[69]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1 (CDKN1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[81]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[82]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[83]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[84]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[58]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[85]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[86]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[87]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[88]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[89]

Drug(s) Affected By Biotin--protein ligase (HLCS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[90]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[91]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[4]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[92]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[91]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[93]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[94]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[95]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[96]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[90]

Drug(s) Affected By 6-phosphogluconate dehydrogenase, decarboxylating (PGD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[51]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[54]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[92]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[97]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[98]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[99]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[100]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[94]
Methylene blue	DMJAPE7	Acquired methemoglobinemia	3A93	Approved	[101]
Benzoic Acid	DMKB9FI	Alopecia areata	ED70.2	Approved	[99]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Carbonic anhydrase (CA)	TTUNARX	NOUNIPROTAC	Inhibitor	[1]
Carbonic anhydrase I (CA-I)	TTHQPL7	CAH1_HUMAN	Inhibitor	[1]
Carbonic anhydrase II (CA-II)	TTANPDJ	CAH2_HUMAN	Inhibitor	[1]
Carbonic anhydrase IV (CA-IV)	TTZHA0O	CAH4_HUMAN	Inhibitor	[1]
Carbonic anhydrase IX (CA-IX)	TT2LVK8	CAH9_HUMAN	Inhibitor	[1]
Carbonic anhydrase VI (CA-VI)	TTCFSPE	CAH6_HUMAN	Inhibitor	[1]
Carbonic anhydrase XII (CA-XII)	TTSYM0R	CAH12_HUMAN	Inhibitor	[1]
Carbonic anhydrase XIV (CA-XIV)	TTEYTKG	CAH14_HUMAN	Inhibitor	[1]
Monoamine oxidase type B (MAO-B)	TTGP7BY	AOFB_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
6-phosphogluconate dehydrogenase, decarboxylating (PGD)	OTVG296F	6PGD_HUMAN	Gene/Protein Processing	[3]
Biotin--protein ligase (HLCS)	OTPDUX30	BPL1_HUMAN	Gene/Protein Processing	[4]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Gene/Protein Processing	[5]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Gene/Protein Processing	[5]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Gene/Protein Processing	[5]
Retinoblastoma-associated protein (RB1)	OTQJUJMZ	RB_HUMAN	Post-Translational Modifications	[5]
Stearoyl-CoA desaturase (SCD)	OTB1073G	SCD_HUMAN	Gene/Protein Processing	[6]
Tyrosinase	OTX54MAA	TYRO_HUMAN	Biotransformations	[7]
UDP-glucuronosyltransferase 1A10	OTOTZVEY	UD110_HUMAN	Biotransformations	[8]
UDP-glucuronosyltransferase 1A3	OTUEOER3	UD13_HUMAN	Biotransformations	[8]

References

• [1] Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
• [2] Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
• [3] Investigation of the effects of some phenolic compounds on the activities of glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase from human erythrocytes. J Biochem Mol Toxicol. 2014 Nov;28(11):510-4. doi: 10.1002/jbt.21592. Epub 2014 Aug 6.
• [4] Resveratrol compounds inhibit human holocarboxylase synthetase and cause a lean phenotype in Drosophila melanogaster. J Nutr Biochem. 2015 Nov;26(11):1379-84. doi: 10.1016/j.jnutbio.2015.07.004. Epub 2015 Jul 26.
• [5] Ferulic acid inhibits endothelial cell proliferation through NO down-regulating ERK1/2 pathway. J Cell Biochem. 2004 Dec 15;93(6):1203-9. doi: 10.1002/jcb.20281.
• [6] Anti-inflammatory effects of dietary phenolic compounds in an in vitro model of inflamed human intestinal epithelium. Chem Biol Interact. 2010 Dec 5;188(3):659-67.
• [7] Biochemical mechanism of caffeic acid phenylethyl ester (CAPE) selective toxicity towards melanoma cell lines. Chem Biol Interact. 2010 Oct 6;188(1):1-14. doi: 10.1016/j.cbi.2010.05.018. Epub 2010 Jun 4.
• [8] Gastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylation. J Biol Chem. 2004 Jul 2;279(27):28320-9. doi: 10.1074/jbc.M401396200. Epub 2004 Apr 26.
• [9] Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
• [10] Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
• [11] Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
• [12] Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
• [13] An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities. Mol Cancer Ther. 2020 Aug;19(8):1660-1669.
• [14] Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
• [15] Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
• [16] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2597).
• [18] Understanding the Dual Inhibition of COX-2 and Carbonic Anhydrase-II by Celecoxib and CG100649 Using Density Functional Theory Calculations and other Molecular Modelling Approaches. Protein Pept Lett. 2015;22(10):903-12.
• [19] Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26.
• [20] Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
• [21] Localization of diuretic effects along the loop of Henle: an in vivo microperfusion study in rats. Clin Sci (Lond). 2000 Apr;98(4):481-8.
• [22] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [23] Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int. 1996 Nov;50(5):1476-82.
• [24] Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50.
• [25] Nature of the inhibition of carbonic anhydrase by acetazolamide and benzthiazide. J Pharmacol Exp Ther. 1961 Mar;131:271-4.
• [26] Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
• [27] Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6.
• [28] Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for th... Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73.
• [29] Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5.
• [30] Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740.
• [31] Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54.
• [32] Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):573-8.
• [33] Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-assoc... Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23.
• [34] Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics. 2012;6:395-407.
• [35] Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V, and IX with anions isosteric and isoelectronic with sulfate, nitrate, and carbo... Bioorg Med Chem Lett. 2005 Feb 1;15(3):567-71.
• [36] Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol Cancer Ther. 2012 Feb;11(2):340-9.
• [37] Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int J Mol Sci. 2013 May 29;14(6):11402-23.
• [38] Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
• [39] Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
• [40] Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
• [41] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
• [42] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [43] Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
• [44] Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
• [45] Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
• [46] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [47] Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.
• [48] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [49] Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells. Neurosci Lett. 2006 Mar 13;395(3):185-90. doi: 10.1016/j.neulet.2005.10.096. Epub 2005 Dec 1.
• [50] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [51] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [52] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [53] Effects of four-week high-fructose diet on gene expression in skeletal muscle of healthy men. Diabetes Metab. 2008 Feb;34(1):82-5. doi: 10.1016/j.diabet.2007.08.004. Epub 2007 Dec 11.
• [54] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [55] Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase. Exp Biol Med (Maywood). 2008 Nov;233(11):1433-40. doi: 10.3181/0804-RM-127. Epub 2008 Sep 12.
• [56] Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011 Apr 28;18(3):333-45. doi: 10.1530/ERC-10-0262. Print 2011 Jun.
• [57] Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Environ Toxicol. 2018 Nov;33(11):1153-1159.
• [58] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [59] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [60] Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012 Aug 15;18(16):4345-55. doi: 10.1158/1078-0432.CCR-11-3227. Epub 2012 Jun 25.
• [61] Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells. Cancer Lett. 2007 Jan 8;245(1-2):103-11. doi: 10.1016/j.canlet.2005.12.034. Epub 2006 Feb 20.
• [62] Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance. Exp Cell Res. 2012 Jun 10;318(10):1146-59.
• [63] HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects. J Pharmacol Exp Ther. 2008 Jan;324(1):352-9. doi: 10.1124/jpet.107.128959. Epub 2007 Oct 10.
• [64] Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
• [65] Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
• [66] Progesterone increases csk homologous kinase in HMC-1560 human mast cells and reduces cell proliferation. J Cell Biochem. 2007 Dec 1;102(5):1271-80. doi: 10.1002/jcb.21357.
• [67] Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017 Aug 1;273:107-114. doi: 10.1016/j.cbi.2017.06.005. Epub 2017 Jun 7.
• [68] Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
• [69] Growth stimulation of human pulmonary adenocarcinoma cells and small airway epithelial cells by beta-carotene via activation of cAMP, PKA, CREB and ERK1/2. Int J Cancer. 2006 Mar 15;118(6):1370-80. doi: 10.1002/ijc.21537.
• [70] Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol. 2014 Mar 1;275(2):176-81. doi: 10.1016/j.taap.2014.01.005. Epub 2014 Jan 17.
• [71] Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins ras and rac-1. J Pharmacol Exp Ther. 2004 Dec;311(3):1232-40. doi: 10.1124/jpet.104.071332. Epub 2004 Jul 19.
• [72] Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
• [73] Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. Int Arch Allergy Immunol. 2011;155(1):38-51. doi: 10.1159/000318720. Epub 2010 Nov 25.
• [74] SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial Cells. Antioxid Redox Signal. 2016 Feb 20;24(6):329-43. doi: 10.1089/ars.2015.6331. Epub 2015 Nov 10.
• [75] Downregulation of mitogen-activated protein kinases (MAPKs) in chronic ethanol-induced fatty liver. Toxicol Mech Methods. 2020 Jul;30(6):407-416. doi: 10.1080/15376516.2020.1747126. Epub 2020 Apr 1.
• [76] A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16657-62. doi: 10.1073/pnas.0707936104. Epub 2007 Oct 9.
• [77] The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
• [78] Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem. 2005 Sep 9;280(36):31498-507. doi: 10.1074/jbc.M505537200. Epub 2005 Jul 13.
• [79] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [80] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [81] Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005 Mar;20(2):139-46. doi: 10.1093/mutage/gei019. Epub 2005 Mar 22.
• [82] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [83] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [84] Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
• [85] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [86] Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
• [87] Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
• [88] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [89] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [90] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [91] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [92] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [93] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [94] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [95] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [96] Chromium(VI) causes down regulation of biotinidase in human bronchial epithelial cells by modifications of histone acetylation. Toxicol Lett. 2011 Aug 28;205(2):140-5. doi: 10.1016/j.toxlet.2011.05.1032. Epub 2011 May 27.
• [97] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [98] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [99] Keratinocyte gene expression profiles discriminate sensitizing and irritating compounds. Toxicol Sci. 2010 Sep;117(1):81-9.
• [100] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [101] Defenses against oxidation in human erythrocytes: role of glutathione reductase in the activation of glucose decarboxylation by hemolytic drugs. J Lab Clin Med. 1991 Apr;117(4):325-31.